{"nctId":"NCT04820530","briefTitle":"Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy","startDateStruct":{"date":"2021-07-19","type":"ACTUAL"},"conditions":["Paroxysmal Nocturnal Hemoglobinuria (PNH)"],"count":40,"armGroups":[{"label":"LNP023","type":"EXPERIMENTAL","interventionNames":["Drug: Iptacopan (LNP023)"]}],"interventions":[{"name":"Iptacopan (LNP023)","otherNames":["Iptacopan"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female participants ≥ 18 years of age with a diagnosis of PNH confirmed by high-sensitivity flow cytometry with RBCs and WBCs clone size ≥ 10%\n* Mean hemoglobin level \\<10 g/dL\n* LDH \\> 1.5 x Upper Limit of Normal (ULN)\n* Vaccination against Neisseria meningitidis infection is required prior to the start of study treatment\n* If not received previously, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given\n\nExclusion Criteria:\n\n* Prior treatment with a complement inhibitor, including anti-C5 antibody\n* Known or suspected hereditary complement deficiency\n* History of hematopoietic stem cell transplantation\n* Patients with laboratory evidence of bone marrow failure (reticulocytes \\<100x109/L; platelets \\<30x109/L; neutrophils \\<0.5x109/L).\n* Active systemic bacterial, viral (incl. COVID-19)or fungal infection within 14 days prior to study drug administration.\n* History of recurrent invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus.\n* Major concurrent comorbidities including but not limited to severe kidney disease (e.g., dialysis), advanced cardiac disease (e.g., NYHA class IV heart failure), severe pulmonary disease (e.g., severe pulmonary hypertension (WHO class IV)), or hepatic disease (e.g., active hepatitis) that in the opinion of the investigator precludes participant's participation in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Marginal Proportion (Expressed as Percentage) of Participants With Sustained Increase in Hemoglobin Levels From Baseline of ≥ 2 g/dL in the Absence of Red Blood Cell Transfusions","description":"Sustained increase in hemoglobin levels (responder) is defined as an increase from baseline in hemoglobin levels of ≥ 2 g/dL on three out of four measurements between Day 126 and 168 of the core treatment period, without requiring red blood cell (RBC) transfusions between Day 14 and Day 168. Requiring RBC transfusions refers to any patient receiving transfusions or meeting protocol defined criteria (Hemoglobin level of ≤9 g/dL (≤8 g/dL for Chinese population) with signs and or symptoms of sufficient severity to warrant a transfusion or Hemoglobin of ≤7 g/dL (≤6 g/dL for Chinese population), regardless of presence of clinical signs and/or symptoms).\n\nThe term 'marginal proportion' can be interpreted as the population average probability of being a responder. Results incorporated a method to handle missing data using multiple imputation. Hence, all 40 patients enrolled contributed to the primary analysis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Marginal Proportion (Expressed as Percentage) With Sustained Hemoglobin Levels of ≥ 12 g/dL in the Absence of Red Blood Cell Transfusions","description":"Sustained hemoglobin levels (responder) is defined as hemoglobin levels ≥ 12 g/dL on three out of four measurements between Day 126 and 168 of the core treatment period, without requiring red blood cell (RBC) transfusions between Day 14 and Day 168. Requiring RBC transfusions refers to any patient receiving transfusions or meeting protocol defined criteria (Hemoglobin level of ≤9 g/dL (≤8 g/dL for Chinese population) with signs and or symptoms of sufficient severity to warrant a transfusion or Hemoglobin of ≤7 g/dL (≤6 g/dL for Chinese population), regardless of presence of clinical signs and/or symptoms).\n\nThe term 'marginal proportion' can be interpreted as the population average probability of being a responder. Results incorporated a method to handle missing data using multiple imputation. Hence, all 40 patients enrolled contributed to the analysis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Marginal Proportion (Expressed as Percentage) of Participants Who Remain Free From Transfusions","description":"Marginal proportion (expressed as percentage) of participants who did not require transfusions between Day 14 and Day 168.\n\nRequiring RBC transfusions refers to any patient receiving transfusions or meeting protocol defined criteria (Hemoglobin level of ≤9 g/dL (≤8 g/dL for Chinese population) with signs and or symptoms of sufficient severity to warrant a transfusion or Hemoglobin of ≤7 g/dL (≤6 g/dL for Chinese population), regardless of presence of clinical signs and/or symptoms). The term 'marginal proportion' can be interpreted as the population average probability of being a responder.\n\nThe 95% CI was obtained using the bootstrap method","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hemoglobin Levels in the Core Treatment Period","description":"Change from baseline in hemoglobin levels as mean of visits between Day 126 and Day 168.\n\nIn order to factor out the effect of transfusions in this analysis, if a patient had a transfusion during the core treatment period, the hemoglobin (Hb) values during 30 days following the transfusion were excluded and Hb data were imputed.\n\nChange from baseline was analyzed using a mixed model of repeated measures which included age (indicator variable of age ≥ 45 years), sex, history of transfusion (yes/no) prior to study treatment, visit, and baseline hemoglobin as fixed effects and the interaction between visit and baseline hemoglobin levels.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.28","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDH","description":"Percent change from baseline in lactate dehydrogenase (LDH) levels as mean of visits between Day 126 and Day 168.\n\nPercentage change from baseline was analyzed using a mixed model for repeated measures (MMRM) which includes age (indicator variable of age ≥ 45 years), sex, history of transfusion (yes/no) prior to study treatment, visit, baseline LDH as fixed effects and visit\\*baseline LDH as interaction.\n\nResults incorporated a method to handle missing data using multiple imputation. Hence, all 40 patients enrolled contributed to the analysis.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-83.55","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Annualized Clinical BTH Rate in the Core Treatment Period","description":"Adjusted annualized rate of clinical breakthrough hemolysis (BTH) events is carried out using the Wilson method. The breakthrough is defined clinical if either there is a decrease in hemoglobin levels equal to or more than 2 g/dL (compared to the latest assessment, or within 15 days) or if patients present signs or symptoms of gross hemoglobinuria, painful crisis, dysphagia or any other significant clinical PNH-related signs \\& symptoms, in presence of laboratory evidence of intravascular hemolysis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Absolute Reticulocyte Count","description":"Change from baseline in absolute reticulocyte counts as mean of visits between Day 126 and Day 168.\n\nChange from baseline was analyzed using a MMRM which includes age (indicator variable of age ≥ 45 years), sex, history of transfusion (yes/no) prior to study treatment, visit, baseline reticulocyte counts as fixed effects and visit\\*baseline reticulocyte counts as interaction.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-82.48","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FACIT-Fatigue Score","description":"Change from baseline in FACIT-Fatigue scores as mean of visits between Day 126 and Day 168. The FACIT-Fatigue is a 13-item questionnaire with support for its validity and reliability in PNH that assesses patient self-reported fatigue and its impact on daily activities and function. All FACIT scales are scored so that a high score is better. As each of the 13 items of the FACIT-F Scale ranges from 0-4, the range of possible scores is 0-52, with 0 being the worst possible score and 52 the best.\n\nChange from baseline was analyzed using a Mixed Model of Repeated Measures (MMRM) which includes age (indicator variable of age ≥ 45 years), sex, history of transfusion (yes/no) prior to study treatment, visit, baseline FACIT-Fatigue score as fixed effects and visit\\*baseline FACIT-Fatigue score as interaction.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.75","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Annualized Major Adverse Vascular Events Rate in the Core Treatment Period","description":"Adjusted annual rate is carried out using the Wilson method. A MAVE is defined as: acute peripheral vascular occlusion, amputation (non-traumatic; nondiabetic), cerebral arterial occlusion/cerebrovascular accident, cerebral venous occlusion, dermal thrombosis, gangrene (non-traumatic; nondiabetic), hepatic/portal vein thrombosis (Budd-Chiari syndrome), mesenteric/visceral arterial, thrombosis or infarction, mesenteric/visceral vein thrombosis or infarction, myocardial infarction, pulmonary embolus, renal arterial thrombosis, renal vein thrombosis, thrombophlebitis / deep vein thrombosis, transient ischemic attack, unstable angina or other.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Patients Meeting Hematological Response Criteria Irrespective of RBC Transfusions","description":"Patients with hematological response are those with an increase in Hb from baseline ≥ 2g/dL irrespective of red blood cell (RBC) transfusions and patients achieving Hb ≥ 12g/dL irrespective of RBC transfusions.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Marginal Proportion (Expressed as Percentage) of Patients Not Receiving and Not Requiring RBC Transfusions","description":"Requiring Red Blood Cells (RBC) transfusions refers to any patient receiving transfusions or meeting protocol defined criteria (Hemoglobin level of ≤9 g/dL (≤8 g/dL for Chinese population) with signs and or symptoms of sufficient severity to warrant a transfusion or Hemoglobin of ≤7 g/dL (≤6 g/dL for Chinese population), regardless of presence of clinical signs and/or symptoms).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Hemoglobin Levels","description":"Change from baseline in Hemoglobin at Visit Day 336","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.09","spread":"2.010"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in LDH at Visit Day 336","description":"Change from baseline in Lactate dehydrogenase (LDH) at Visit Day 336","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1393.3","spread":"652.15"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Adjusted Annualized Clinical BTH Rate After the Start of LNP023 Treatment","description":"Adjusted annualized rate of clinical breakthrough hemolysis (BTH) events is carried out using the Wilson method. The breakthrough is defined clinical if either there is a decrease in hemoglobin levels equal to or more than 2 g/dL (compared to the latest assessment, or within 15 days) or if patients present signs or symptoms of gross hemoglobinuria, painful crisis, dysphagia or any other significant clinical PNH-related signs \\& symptoms, in presence of laboratory evidence of intravascular hemolysis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Absolute Reticulocyte Count at Day 336","description":"Change from baseline in absolute reticulocyte count at visit Day 336.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-76.55","spread":"50.149"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in FACIT-Fatigue Score","description":"The FACIT-Fatigue is a 13-item questionnaire with support for its validity and reliability in PNH that assesses patient self-reported fatigue and its impact on daily activities and function. All FACIT scales are scored so that a high score is better. As each of the 13 items of the FACIT-F Scale ranges from 0-4, the range of possible scores is 0-52, with 0 being the worst possible score and 52 the best.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"10.14"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Adjusted Annualized Major Adverse Vascular Events Rate After the Start of LNP023 Treatment","description":"Adjusted annual rate is carried out using the Wilson method. A Major Adverse Vascular Events (MAVE) is defined as: acute peripheral vascular occlusion, amputation (non-traumatic; nondiabetic), cerebral arterial occlusion/cerebrovascular accident, cerebral venous occlusion, dermal thrombosis, gangrene (non-traumatic; nondiabetic), hepatic/portal vein thrombosis (Budd-Chiari syndrome), mesenteric/visceral arterial, thrombosis or infarction, mesenteric/visceral vein thrombosis or infarction, myocardial infarction, pulmonary embolus, renal arterial thrombosis, renal vein thrombosis, thrombophlebitis / deep vein thrombosis, transient ischemic attack, unstable angina or other","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":40},"commonTop":["Headache","COVID-19","Upper respiratory tract infection","Diarrhoea","Abdominal pain"]}}}